Opportunity Assessment: GLP-1 Receptor Agonists in the Egyptian Market
300,00 $
Glucagon-like peptide-1 (GLP-1) receptor agonists are the fastest-growing therapeutic frontier in the Egyptian pharmaceutical market. The class expanded from roughly EGP 144 million in 2021 to approximately EGP 3.26 billion on a Moving Annual Total (MAT) basis to December 2025 — a four-year compound annual growth rate (CAGR) of about 118 percent. Opportunity score: 88 / 100
Description
PHARMACEUTICAL MARKET RESEARCH PROGRAM
Opportunity Assessment: GLP-1 Receptor Agonists in the Egyptian Market
Egypt’s fastest-growing therapeutic frontier.
Data: audited market sales, Egypt, MAT 2021 to 2025. Product rankings, MAT December 2025. YTD April 2026.
Key Figures
- Opportunity score: 88 / 100, the highest in the program to date
- Market size: approximately EGP 3.26 billion (MAT to December 2025), up from roughly EGP 144 million in 2021
- Growth: a four-year compound annual growth rate (CAGR) of about 118 percent
- Treated population context: roughly 10.9 million adults with diabetes
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are the fastest-growing therapeutic frontier in the Egyptian pharmaceutical market. In sharp contrast to the mature core of the market, this growth is majority real volume rather than a currency artifact. Unit demand is expanding rapidly, driven by Egypt’s exceptionally high burden of type 2 diabetes and obesity.
Market structure
The class is an originator duopoly. MOUNJARO (tirzepatide) and OZEMPIC (semaglutide) together define the category. MOUNJARO has effectively doubled from a standing start, and OZEMPIC has grown units by about 61 percent. Both brands are supply-constrained rather than demand-constrained: the binding limits are manufacturing allocation and price accessibility, not patient appetite.
Clinical evidence
The evidence base is unusually strong. Head-to-head randomized trials establish tirzepatide’s superiority over semaglutide on both glycemic control and weight reduction, and dedicated obesity trials show weight loss of 15 to 23 percent.
Headroom and constraints
Against a diabetic population of roughly 10.9 million adults and a far larger obese and overweight pool, current treated penetration is a small fraction of the eligible base, which implies years of structural headroom. We assign an opportunity score of 88 out of 100, reflecting genuine volume growth, a durable clinical rationale and large unmet demand. Supply constraints, affordability ceilings in a devaluing currency and originator dominance temper the score and narrow the near-term entry window to biosimilar and access-led plays.
Request the full report or a market assessment for your product. See our market research and consultation services. Related report: Colchicine in the Egyptian market.
